New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated
source: pixabay.com

New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated

Antigen-specific T-cell therapy is an innovative treatment option which uses immune cells to combat cancer cells. AdventHealth is the very first in the world to use this treatment for patients…

Continue Reading New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated
Novel Immunotherapy Treatment for AML and MDS Developed by AdventHealth
source: pixabay.com

Novel Immunotherapy Treatment for AML and MDS Developed by AdventHealth

Orlando-based healthcare company AdventHealth developed a novel immunotherapy treatment designed to treat patients with AML and MDS whose conditions failed to respond to other treatments. In addition, the organization is…

Continue Reading Novel Immunotherapy Treatment for AML and MDS Developed by AdventHealth
Researchers Discover Method to Predict Survival in Low-Risk Myelodysplastic Syndromes
source: pixabay.com

Researchers Discover Method to Predict Survival in Low-Risk Myelodysplastic Syndromes

A recent study published in Blood Cancer Journal has established a new method for effectively predicting survival outcomes for patients with low-risk myelodysplastic syndromes (MDS). The method is known as the…

Continue Reading Researchers Discover Method to Predict Survival in Low-Risk Myelodysplastic Syndromes

MEDALIST Trial: The Need for Blood Transfusions Was Reduced in Myelodysplastic Syndrome Patients

Dr. Pierre Fenaux, of Hôpital Saint Louis, Paris and lead author of the MEDALIST trial, told Ash Clinical News that treatment with the investigational drug, luspatercept, improved the rate of…

Continue Reading MEDALIST Trial: The Need for Blood Transfusions Was Reduced in Myelodysplastic Syndrome Patients
Questions for COVID-19: Should Cancer Patients Attend Appointments?
Photo by National Cancer Institute on Unsplash

Questions for COVID-19: Should Cancer Patients Attend Appointments?

  In a period of unprecedented changes, it is understandable that people may question what their lives may look like moving forward. COVID-19 has now spread to 196 countries and…

Continue Reading Questions for COVID-19: Should Cancer Patients Attend Appointments?
Elderly Patients with Myelodysplastic Syndromes can Have Successful Transplants
source: pixabay.com

Elderly Patients with Myelodysplastic Syndromes can Have Successful Transplants

By Rachel Whetstone from In The Cloud Copy Many patients with myelodysplastic syndromes (MDS) are elderly when they’re diagnosed with the disease. Although stem cell transplants are often thought to…

Continue Reading Elderly Patients with Myelodysplastic Syndromes can Have Successful Transplants
ICYMI: An Observational Blood Cancer Study is Starting to Recruit Patients
source: pixabay.com

ICYMI: An Observational Blood Cancer Study is Starting to Recruit Patients

According to a story from Financial Buzz, the precision oncology company Notable has recently announced that it has opened enrollment for a new observational clinical trial that will focus on…

Continue Reading ICYMI: An Observational Blood Cancer Study is Starting to Recruit Patients
TrialJectory is a New Website Helping to Match Cancer Patients to Clinical Trials
source: pixabay.com

TrialJectory is a New Website Helping to Match Cancer Patients to Clinical Trials

TrialJectory is an organization working to match bladder, breast, colorectal, melanoma, myelodysplastic syndromes (MDS), and other cancer patients with the clinical trial that is right for them. They have successfully raised…

Continue Reading TrialJectory is a New Website Helping to Match Cancer Patients to Clinical Trials

Experimental Myelodysplastic Syndrome Treatment Receives Breakthrough Therapy Designation

  A drug created by Agios Pharmaceuticals, TIBSOVO, was recently granted the Breakthrough Therapy designation by the FDA for the treatment of relapsed or refractory myelodysplastic syndrome (MDS) with an…

Continue Reading Experimental Myelodysplastic Syndrome Treatment Receives Breakthrough Therapy Designation
FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes
source: pixabay.com

FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes

According to a story from BioPortfolio, Acceleron Pharma and the Bristol-Myers Squibb Company have announced recently that the US Food and Drug Administration (FDA) will review the supplemental Biologics License…

Continue Reading FDA Committee to Hold Review for Reblozyl as a Treatment for Myelodysplastic Syndromes
Experimental Treatment for Pancreatic Cancer has Earned Orphan Drug Designation
source: pixabay.com

Experimental Treatment for Pancreatic Cancer has Earned Orphan Drug Designation

According to a story from BioSpace, the biopharmaceutical company CrystalGenomics, Inc. recently announced that the US Food and Drug Administration (FDA) has granted the company's investigational drug candidate CG-745 Orphan…

Continue Reading Experimental Treatment for Pancreatic Cancer has Earned Orphan Drug Designation

FDA Approves an Experimental Treatment of Various Blood Malignancies for Clinical Trials

According to a story from First World Pharma, the biopharmaceutical company Mustang Bio, Inc. recently announced that the US Food and Drug Administration (FDA) has approved their investigational new drug…

Continue Reading FDA Approves an Experimental Treatment of Various Blood Malignancies for Clinical Trials

Tips by a Myelodysplastic Syndromes Patient on How to Navigate the Internet When Researching Your Rare Disease

Jane Biehl Jane Biehl has worked as a professor, rehabilitation counselor, and a librarian. She holds three different degrees, and spreads her knowledge through freelance writing. She also has a…

Continue Reading Tips by a Myelodysplastic Syndromes Patient on How to Navigate the Internet When Researching Your Rare Disease

The New 5F9 Antibody Looks Encouraging as it Targets MDS and AML Leukemia in a Phase 1b Clinical Trial

  The California Institute for Regenerative Medicine (CIRM) has funded a study by a company called Forty Seven, Inc. The clinical trial is investigating the benefits of a drug therapy for two cancers…

Continue Reading The New 5F9 Antibody Looks Encouraging as it Targets MDS and AML Leukemia in a Phase 1b Clinical Trial